Diabetic retinopathy (DR), a serious microvascular complication of diabetes,
is a leading cause of blindness in adults. The pathogenesis of DR involves a
variety of tissues and complex mechanisms, such as inflammation, oxidative
stress, optic neurodegeneration, and autophagy. Nowadays, microRNAs
(miRNAs), a novel group of non-coding small RNAs, have been extensively
studied and recognized to play a key role in the pathogenesis of DR through
aforementioned pathways. Furthermore, some miRNAs have been proposed as
biomarkers that may be utilized to screen for DR. Also, miRNAs are a new
therapy for DR. In this review, we summarize several miRNAs and, their roles
in the pathogenesis of DR. miRNAs, as potential pharmacological targets for
the diabetic retinopathy, may provide new insights for the treatment of
DR.